For this third webinar, we are pleased to welcome the esteemed Roland Derwand, MD, MBA, from Munich Germany. The webinar is mostly focused on the study about COVID-19 outpatients as treated by Dr Zev Zelenko in NY State.
The study is co-authored with Professor Martin Scholz, PhD, and Dr Vladimir Zelenko. The study is now peer-reviewed and accepted as pre-proof in the International Journal of Antimicrobial Agents.
Dr Derwand presents how the study was conducted and what are the most salient points one needs to draw from it. He puts particular emphasis on the role of Zinc – an agent that Dr Zelenko included very early on in his treatment protocol, and which is now widely recognized as essential for the early treatment of COVID-19.
Dr Derwand follows by commenting on the situation with COVID-19 in Germany and the therapeutic approaches the country has adopted to fight the disease.
Dr Derwand also comments on the treatment protocols and risk stratification approach used in Bahrain, which may be an example to follow in other jurisdictions.
For the Q&A session, we Prof Martin Scholz and Dr Zev Zelenko joined Dr Derwand.
For a shorter version, limited to Dr Derwand’s PowerPoint presentation, please click here.
Please refer to the study by Dr Derwand, Prof Scholz and Dr Zelenko, as published in the International Journal of Antimicrobial Agents: “COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study”